about
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.Liraglutide for treating type 1 diabetes.Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.Emerging drugs for the treatment of obesity.Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.Levels of the inflammation marker YKL-40 in young adults exposed to intrauterine hyperglycemia.Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men.Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy.Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapyLiraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trialEffect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial
P50
Q35331836-EDBA9DCC-23C1-4E85-8AEC-051892C0D654Q35939660-88743142-375D-420E-9FCD-18DC266F9DF6Q38770952-7B84B6D6-CD58-427B-A30D-C8A53C0BE5CBQ39031756-ABB21C3C-F4B6-4770-9F76-1BD30966F3EFQ39204459-DECADB48-AADF-4DD6-951B-B28B5BFEAE7AQ40223075-D15F88AE-9C73-41C0-9B18-0EFF08EB55ECQ40432883-5827BE7A-EBA1-4E91-8B79-77B9273FF895Q40786726-602407CC-AA66-44FF-AB1A-6EE99631706FQ42259848-2A342464-ADB4-4C55-91C8-37F4692CFE22Q46124325-D006D5A9-E1F7-44E4-A14E-540B1D9F1123Q47352844-55F63810-67DD-4E77-84CF-DD0C8DAF860CQ47826603-B225D29B-6CFD-464C-B8F1-886AF3BCEC05Q51055764-856AA6FE-6A42-491F-AB4C-836465463731Q58167053-E9A9EDFE-2730-4905-B2DB-1DA5C4AE28B8Q91159217-0136F683-F966-4B84-B28A-0F1124762D55Q96434494-C8F7318B-DF0A-4B57-88D7-2BEE535FB85B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Fremming Dejgaard
@ast
Thomas Fremming Dejgaard
@en
Thomas Fremming Dejgaard
@es
Thomas Fremming Dejgaard
@nl
Thomas Fremming Dejgaard
@sl
type
label
Thomas Fremming Dejgaard
@ast
Thomas Fremming Dejgaard
@en
Thomas Fremming Dejgaard
@es
Thomas Fremming Dejgaard
@nl
Thomas Fremming Dejgaard
@sl
prefLabel
Thomas Fremming Dejgaard
@ast
Thomas Fremming Dejgaard
@en
Thomas Fremming Dejgaard
@es
Thomas Fremming Dejgaard
@nl
Thomas Fremming Dejgaard
@sl
P108
P106
P21
P31
P496
0000-0002-0097-7052